Recent Updates
Recently added Catalysts

LY4292009

Phase 1

Undisclosed | Small molecule | Other |Eli Lilly and Company|Trials Updated: Apr 17, 2026

LY4292009 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since May 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedPLACEBO_CONTROLLED
Total Trials1
Total Enrollment80

FDA Designations

No designations recorded

LY4292009 clinical trials

LY4292009 · 1 trial · 1 indication

Phase 1 1
NCT06977880A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy ParticipantsHealthy
COMPLETED80 Analytics
PHASE1COMPLETED
A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants
Healthy
NCT0697788080
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Event (SAEs) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)
Baseline to Study Completion (Up to Day 17)
Percentage of Participants with TEAEs and SAEs in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)
Baseline to Study Completion (Up to Day 7)
Number of Participants with One or More Serious Adverse Event(s) (SAEs) in (Cohort A1-A6) and MAD (Cohort B1-B4)
Baseline to Study Completion (Up to Day 7)
Change from Baseline in Laboratory Parameter and Vital Signs in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)
Baseline to Study Completion (Up to Day 7)
Number of Participants with Clinically Significant Changes in Cardiovascular Evaluation in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)
Baseline to Study Completion (Up to Day 7)

Secondary Endpoints

Pharmacokinetics (PK): Maximum Concentration (Cmax) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)
SAD Cohorts: Predose up to Day 4 Postdose
PK: Time to Maximum Concentration (Tmax) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)
SAD Cohorts: Predose up to Day 4 Postdose
PK: Area Under the Concentration Curve (AUC) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)
SAD Cohorts: Predose up to Day 4 Postdose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Cohort A1EXPERIMENTALParticipants received LY4292009 orally.
Cohort A2EXPERIMENTALParticipants received LY4292009 orally.
Cohort A3EXPERIMENTALParticipants received LY4292009 orally.
Cohort A4EXPERIMENTALParticipants received LY4292009 orally.
Cohort A5EXPERIMENTALParticipants received LY4292009 orally.
Cohort A6 (Optional)EXPERIMENTALParticipants received LY4292009 orally.
Cohort B1EXPERIMENTALParticipants received LY4292009 orally.
Cohort B2EXPERIMENTALParticipants received LY4292009 orally.
Cohort B3EXPERIMENTALParticipants received LY4292009 orally.
Cohort B4 (Optional)EXPERIMENTALParticipants received LY4292009 orally.
PlaceboPLACEBO_COMPARATORParticipants receive placebo.

Interventions

NameTypeDescription
LY4292009DRUGAdministered orally
PlaceboDRUGAdministered orally.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Body mass index (BMI) within 18.0 kg/m² to 30.0 kg/m², inclusive * If male, meets one of the following: * can procreate and agree to use one of the accepted to use one of the accepted contraceptive regimens and not to donate sperm from the first study drug administration to...

Countries:Canada
Unlock Eligibility Criteria

Frequently asked questions about LY4292009

What is LY4292009?

LY4292009 is an investigational small molecule being developed by Eli Lilly and Company. It has been studied in a Phase 1 first-in-human trial in healthy participants. The specific disease or condition it is intended to treat has not been disclosed.

Who is developing LY4292009?

LY4292009 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The compound is an investigational small molecule and has completed one Phase 1 clinical trial.

What phase is LY4292009 in?

LY4292009 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The program remains in early clinical development and is not approved for any indication.

What clinical trials is LY4292009 in?

LY4292009 has been evaluated in one clinical trial, NCT06977880, titled a Phase 1 first-in-human study of MORF-440 (LY4292009) in healthy participants. The trial enrolled 80 participants in Canada and has been completed.

Is LY4292009 the same as MORF-440?

Yes, LY4292009 is also known as MORF-440. The Phase 1 first-in-human trial is titled a study of MORF-440 (LY4292009), confirming that both names refer to the same investigational small molecule developed by Eli Lilly and Company.

What was the design of the LY4292009 Phase 1 trial?

The Phase 1 trial NCT06977880 was a first-in-human study of LY4292009 in healthy participants. It enrolled 80 participants, was randomized and placebo-controlled, and was conducted in Canada. The study has been completed.

Explore more on BiopharmaWatch

Eli Lilly and Company (LLY)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with LCompanies A to ZEvery biotech and pharma company we track